Multiplexed Droplet Digital Nucleic Acid Amplification Technologies for HIV Diagnosis

用于 HIV 诊断的多重液滴数字核酸扩增技术

• 批准号: 10927089
• 负责人: ROBIN PRINCE
• 金额: $ 29.99万
• 依托单位: FLUID DISCOVERY INC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10927089
• 关键词: Address; Biological Assay; Contracts; Development; Diagnostic; Goals; HIV Infections; HIV diagnosis; Highly Active Antiretroviral Therapy; Human immunodeficiency virus test; Individual; Laboratories; Nucleic Acid Amplification Tests; Nucleic Acids; Sensitivity and Specificity; Serology; Technology; Testing; Vaccines; acute infection; clinical practice; digital; experience; next generation; point of care; programs; self testing; seropositive

Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be developed to address one or all applications/indications of HIV tests, namely: (1) laboratory based tests; ((2) point-of-care and clinical practices; and (3) self-testing. This contract aims to develop a droplet digital nucleic acid test to diagnose HIV infection.

发展区分HIV感染和疫苗诱导的血清阳性的诊断学：该计划的总体目标是支持新的血清学和核酸分析的发展，这些方法可以识别HIV感染，同时避免由于疫苗诱导的血清阳性(VISP)而导致的假阳性结果，具有高度的敏感性和特异性。这些下一代检测方法应针对艾滋病毒检测的一个或所有应用/适应症，即：(1)基于实验室的检测；(2)护理点和临床实践；以及(3)自我检测。这份合同旨在开发一种液滴数字核酸测试来诊断艾滋病毒感染。